[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 9 of about 9
1. Mosqueda Taylor A, Meneses García A, Ruíz Godoy Rivera LM, Suárez Roa Mde L, Luna Ortiz K: Malignant odontogenic tumors. A retrospective and collaborative study of seven cases. Med Oral; 2003 Mar-Apr;8(2):110-21

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant odontogenic tumors. A retrospective and collaborative study of seven cases.
  • The frequency, clinico-pathologic features and outcome of malignant odontogenic tumors diagnosed according to the current WHO classification in three pathology services in Mexico City are presented.
  • There were seven cases (5 male and 2 female patients), which represent less than 4% of all odontogenic tumors diagnosed in these services.
  • There were six odontogenic carcinomas (two malignant ameloblastomas, two clear cell odontogenic carcinomas, one primary intraosseous carcinoma and one carcinoma arising in an odontogenic cyst) and one ameloblastic fibrosarcoma.
  • Clear cell odontogenic carcinomas occurred in the canine-premolar region, one in the maxilla and one in the mandible (one ia a man and one in a woman), while the remaining lesions affected the posterior region of the mandible, with a male predominance (4:1), which agrees with previously reported cases.
  • Surgical resection was the treatment employed in all carcinomas, while the ameloblastic fibrosarcoma was treated with chemotherapy due to its large extension, but without favorable response.
  • The patient with primary intraosseous carcinoma had submaxillary and cervical metastases and the neoplasm was the cause of death.
  • In spite of their extremely low frequency, malignant odontogenic tumors are an important cause of extensive surgical procedures in the oral and maxillofacial region.
  • [MeSH-major] Odontogenic Tumors / pathology
  • [MeSH-minor] Adenocarcinoma, Clear Cell / pathology. Adult. Aged. Ameloblastoma / pathology. Female. Humans. Male. Mandibular Neoplasms / pathology. Middle Aged. Odontogenic Cysts / pathology. Prospective Studies. Retrospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12618671.001).
  • [ISSN] 1137-2834
  • [Journal-full-title] Medicina oral : órgano oficial de la Sociedad Española de Medicina Oral y de la Academia Iberoamericana de Patología y Medicina Bucal
  • [ISO-abbreviation] Med Oral
  • [Language] eng; spa
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] Spain
  •  go-up   go-down


2. Ram H, Mohammad S, Husain N, Gupta PN: Ameloblastic carcinoma. J Maxillofac Oral Surg; 2010 Dec;9(4):415-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Ameloblastic carcinoma (AC) is a rare aggressive malignant epithelial odontogenic tumor of the maxillofacial skeleton with a distinct predilection in the mandible.
  • It may appear de novo or originate from a pre-existing ameloblastoma or odontogenic cyst.
  • It may present as a cystic lesion with benign clinical features or as a large tissue mass with ulceration, significant bone resorption and tooth mobility.
  • Direct extension of the tumour, lymph node involvement and metastasis to various sites has been reported.
  • Wide local excision is the treatment of choice.
  • Regional lymph node dissection should be considered and performed selectively.
  • Radiotherapy and chemotherapy have limited role in the treatment of ameloblastic carcinomas.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 22190836.001).
  • [ISSN] 0974-942X
  • [Journal-full-title] Journal of maxillofacial and oral surgery
  • [ISO-abbreviation] J Maxillofac Oral Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Other-IDs] NLM/ PMC3177477
  • [Keywords] NOTNLM ; Ameloblastic carcinoma / Ameloblastoma / Odontogenic tumor
  •  go-up   go-down


3. Gosau M, Draenert FG, Müller S, Frerich B, Bürgers R, Reichert TE, Driemel O: Two modifications in the treatment of keratocystic odontogenic tumors (KCOT) and the use of Carnoy's solution (CS)--a retrospective study lasting between 2 and 10 years. Clin Oral Investig; 2010 Feb;14(1):27-34
Hazardous Substances Data Bank. CHLOROFORM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Two modifications in the treatment of keratocystic odontogenic tumors (KCOT) and the use of Carnoy's solution (CS)--a retrospective study lasting between 2 and 10 years.
  • This retrospective study aimed at evaluating the recurrence rates of keratocystic odontogenic tumors (KCOTs) that were enucleated with and without the application of Carnoy's solution (CS).
  • Recurrence rates were investigated in correlation with the respective treatment method applied.
  • Additionally, any damage to the inferior alveolar nerve associated with treatment was analyzed.
  • Treatments consisted of enucleation with (38.9%) or without (61.1%) the application of CS.
  • No detrimental effects of CS on the mandibular nerve were detected.
  • The application of CS did not cause any damage to the mandibular nerve.
  • [MeSH-major] Acetic Acid / therapeutic use. Antineoplastic Agents / therapeutic use. Chemotherapy, Adjuvant / methods. Chloroform / therapeutic use. Ethanol / therapeutic use. Jaw Neoplasms / drug therapy. Neoplasm Recurrence, Local / prevention & control. Odontogenic Tumors / drug therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Cautery / methods. Child. Disease-Free Survival. Female. Humans. Kaplan-Meier Estimate. Male. Mandibular Nerve / drug effects. Middle Aged. Neovascularization, Pathologic / drug therapy. Retrospective Studies. Young Adult

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • Hazardous Substances Data Bank. ETHANOL .
  • Hazardous Substances Data Bank. ACETIC ACID .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Clin Oral Investig. 2010 Dec;14(6):719-21 [20838833.001]
  • [Cites] Eur J Cancer B Oral Oncol. 1996 May;32B(3):202-6 [8762878.001]
  • [Cites] Int J Oral Maxillofac Surg. 2007 Jan;36(1):20-5 [17156974.001]
  • [Cites] J Oral Maxillofac Surg. 1985 Mar;43(3):177-82 [2579223.001]
  • [Cites] Hum Genet. 1997 Oct;100(5-6):497-502 [9341860.001]
  • [Cites] J Oral Maxillofac Surg. 1994 Jun;52(6):599-606 [8189298.001]
  • [Cites] Br J Oral Maxillofac Surg. 1997 Feb;35(1):46-8 [9043004.001]
  • [Cites] Oral Oncol. 2002 Jun;38(4):323-31 [12076694.001]
  • [Cites] Nat Genet. 1996 Jan;12(1):85-7 [8528259.001]
  • [Cites] J Can Dent Assoc. 2008 Mar;74(2):165-165h [18353202.001]
  • [Cites] Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2000 Nov;90(5):553-8 [11077375.001]
  • [Cites] Lancet. 1992 Mar 7;339(8793):581-2 [1347096.001]
  • [Cites] J Oral Maxillofac Surg. 2004 Jun;62(6):651-5; discussion 655-6 [15170272.001]
  • [Cites] J Oral Maxillofac Surg. 1992 Jan;50(1):22-6 [1370082.001]
  • [Cites] J Oral Maxillofac Surg. 2005 May;63(5):635-9 [15883937.001]
  • [Cites] Oral Surg Oral Med Oral Pathol. 1991 Sep;72(3):265-9 [1717918.001]
  • [Cites] Mund Kiefer Gesichtschir. 2007 Sep;11(4):221-31 [17641919.001]
  • [Cites] J Oral Maxillofac Surg. 2006 Mar;64(3):379-83 [16487797.001]
  • [Cites] J Oral Maxillofac Surg. 1994 Sep;52(9):960-3 [8064460.001]
  • [Cites] J Dent Res. 1999 Jul;78(7):1345-53 [10403462.001]
  • [Cites] Int J Oral Maxillofac Surg. 1988 Feb;17(1):25-8 [3127485.001]
  • [Cites] J Oral Maxillofac Surg. 2005 Nov;63(11):1662-6 [16243184.001]
  • [Cites] J Oral Maxillofac Surg. 1994 Sep;52(9):964-6 [8064461.001]
  • [Cites] J Oral Sci. 2007 Sep;49(3):229-35 [17928730.001]
  • [Cites] Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2006 Jan;101(1):5-9; discussion 10 [16360602.001]
  • [Cites] J Oral Maxillofac Surg. 2001 Jul;59(7):720-5; discussion 726-7 [11429726.001]
  • [Cites] Med Oral. 2001 Nov-Dec;6(5):350-7 [11694868.001]
  • [Cites] Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2002 Aug;94(2):151-6 [12221380.001]
  • [Cites] Dtsch Zahnarztl Z. 1991 Jan;46(1):80-3 [1725863.001]
  • [Cites] Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2002 Nov;94(5):543-53 [12424446.001]
  • [Cites] Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 1998 Nov;86(5):573-7 [9830650.001]
  • [Cites] Oral Maxillofac Surg Clin North Am. 2003 Aug;15(3):317-24 [18088685.001]
  • [Cites] Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 1998 Jul;86(1):42-7 [9690244.001]
  • [Cites] Int J Oral Maxillofac Surg. 2001 Feb;30(1):14-25 [11289615.001]
  • [Cites] Dtsch Z Mund Kiefer Gesichtschir. 1990 Sep-Oct;14(5):375-7 [2135243.001]
  • [Cites] J Maxillofac Surg. 1981 Nov;9(4):228-36 [6172530.001]
  • [Cites] J Oral Maxillofac Surg. 1984 Jan;42(1):10-9 [6199488.001]
  • [Cites] J Dent Res. 2000 Jun;79(6):1418-22 [10890722.001]
  • (PMID = 19294436.001).
  • [ISSN] 1436-3771
  • [Journal-full-title] Clinical oral investigations
  • [ISO-abbreviation] Clin Oral Investig
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Carnoy's solution; 3K9958V90M / Ethanol; 7V31YC746X / Chloroform; Q40Q9N063P / Acetic Acid
  •  go-up   go-down


Advertisement
4. Zhang L, Zeng D, Huang H, Wang J, Tao Q, Pan C, Xu J, Zhang B, Wang A: Tissue inhibitor of metalloproteinase-2 inhibits ameloblastoma growth in a new mouse xenograft disease model. J Oral Pathol Med; 2010 Jan;39(1):94-102
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tissue inhibitor of metalloproteinase-2 inhibits ameloblastoma growth in a new mouse xenograft disease model.
  • BACKGROUND: Ameloblastomas are odontogenic neoplasms characterized by local invasiveness.
  • This study was conducted to develop a new animal model of ameloblastoma and to address the role of tissue inhibitor of metalloproteinase-2 (TIMP-2) and matrix metalloproteinase-2 (MMP-2) in the growth and invasiveness of ameloblastomas.
  • METHOD: Donated fresh human ameloblastoma tissue was finely minced, screened, and subcutaneously implanted in three locations on each of 10 BALB/c-nu/nu nude mice.
  • Newly established tumors on each mouse were injected with: (i) transfection reagent;.
  • Tumors were monitored for 5 weeks and excised for histopathology, RNA, and protein analyses.
  • CONCLUSIONS: We successfully established a new experimental model of ameloblastoma consisting of subcutaneous human xenografts in nude mice.
  • In addition, we demonstrated the successful introduction of the TIMP-2 gene in tumor xenograft cells in vivo, resulting in xenograft growth inhibition.
  • This growth inhibition may have resulted from TIMP-2 overexpression specifically inhibiting MMP-2 protein expression and activity.
  • [MeSH-major] Ameloblastoma / drug therapy. Neoplasm Transplantation. Soft Tissue Neoplasms / drug therapy. Tissue Inhibitor of Metalloproteinase-2 / therapeutic use. Transplantation, Heterologous
  • [MeSH-minor] Adult. Animals. Blotting, Western. Disease Models, Animal. Female. Genetic Vectors / therapeutic use. Humans. Matrix Metalloproteinase 2. Matrix Metalloproteinase Inhibitors. Mice. Mice, Inbred BALB C. Mice, Nude. Neoplasm Invasiveness. Plasmids / therapeutic use. Reverse Transcriptase Polymerase Chain Reaction. Subcutaneous Tissue / surgery. Transfection. Tumor Cells, Cultured

  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19895658.001).
  • [ISSN] 1600-0714
  • [Journal-full-title] Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology
  • [ISO-abbreviation] J. Oral Pathol. Med.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Matrix Metalloproteinase Inhibitors; 127497-59-0 / Tissue Inhibitor of Metalloproteinase-2; EC 3.4.24.24 / Matrix Metalloproteinase 2; EC 3.4.24.24 / Mmp2 protein, mouse
  •  go-up   go-down


5. Ricard AS, Majoufre-Lefebvre C, Siberchicot F, Laurentjoye M: A multirecurrent ameloblastoma metastatic to the lung. Rev Stomatol Chir Maxillofac; 2010 Apr;111(2):98-100
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • INTRODUCTION: The ameloblastoma is a rare tumor of odontogenic epithelial origin.
  • It is a neoplasm in which ameloblastic features are revealed by the primary growth in jaws and by any metastatic growth.
  • We present a case of a multirecurrent ameloblastoma of the mandible metastatic to the lung.
  • OBSERVATION: We present a case of a mandibular malignant ameloblastoma in a 42-year old man with widespread pulmonary metastases.
  • DISCUSSION: Ameloblastoma metastasis often occurs in the lung.
  • The curative treatment is surgical.
  • The results of palliative chemotherapy and radiotherapy are not always efficient.
  • [MeSH-major] Ameloblastoma / pathology. Ameloblastoma / secondary. Lung Neoplasms / secondary. Mandibular Neoplasms / pathology. Mandibular Neoplasms / surgery
  • [MeSH-minor] Adult. Bone Transplantation. Humans. Lung / surgery. Male. Mandible / surgery. Neoplasm Recurrence, Local / surgery. Reconstructive Surgical Procedures

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20347463.001).
  • [ISSN] 1776-257X
  • [Journal-full-title] Revue de stomatologie et de chirurgie maxillo-faciale
  • [ISO-abbreviation] Rev Stomatol Chir Maxillofac
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] France
  •  go-up   go-down


6. Nakano H, Ota Y, Yura Y: Calcifying epithelial odontogenic tumor of the maxilla with ulcerative stomatitis: a case report. Br J Oral Maxillofac Surg; 2009 Apr;47(3):222-4
Genetic Alliance. consumer health - Calcifying Epithelial Odontogenic Tumor.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Calcifying epithelial odontogenic tumor of the maxilla with ulcerative stomatitis: a case report.
  • Calcifying epithelial odontogenic tumor (CEOT) is a rare benign odontogenic tumor, known as Pindborg tumor.
  • Although ulcer formation was reported in one previously involving the peripheral maxilla, such change of the overlying mucosa has been reported in intraosseous CEOT.
  • We report maxillary CEOT in a patient who complained of spontaneous pain due to extensive ulcer formation of the oral mucosa.
  • [MeSH-major] Gingivitis, Necrotizing Ulcerative / etiology. Maxillary Neoplasms / pathology. Odontogenic Tumors / pathology
  • [MeSH-minor] Adult. Anti-Bacterial Agents / therapeutic use. Anti-Inflammatory Agents, Non-Steroidal / therapeutic use. Calcinosis. Female. Humans. Mouth Mucosa / pathology. Mucositis / drug therapy. Mucositis / etiology. Mucositis / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18790551.001).
  • [ISSN] 1532-1940
  • [Journal-full-title] The British journal of oral & maxillofacial surgery
  • [ISO-abbreviation] Br J Oral Maxillofac Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Scotland
  • [Chemical-registry-number] 0 / Anti-Bacterial Agents; 0 / Anti-Inflammatory Agents, Non-Steroidal
  •  go-up   go-down


7. Sauk JJ, Nikitakis NG, Scheper MA: Are we on the brink of nonsurgical treatment for ameloblastoma? Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2010 Jul;110(1):68-78
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Are we on the brink of nonsurgical treatment for ameloblastoma?
  • OBJECTIVE: Recent identification of altered molecular signaling pathways in neoplasia has begun to elucidate mechanisms of oncogenesis, differentiation, and tumor progression, and to suggest plausible nonsurgical considerations for treatment.
  • Here we review the sonic hedgehog (SHH) and PI3K/Akt/mTOR signaling pathways, their role in ameloblastoma, a locally aggressive odontogenic tumor, and evidence for consideration of therapeutic approaches that target these molecular pathways.
  • STUDY DESIGN: This is a comprehensive review of the literature regarding alterations in signaling mechanisms associated with ameloblastomas.
  • RESULTS: The expression of SHH signaling molecules in ameloblastomas at the mRNA and protein levels has intimated that these molecules may play a role in cell proliferation of these tumors.
  • Immunohistochemical analysis has revealed aberrant signaling in the PI3K/Akt/mTOR pathway in ameloblastomas and appears to be a valuable tool for elucidating pathogenesis and aggressiveness, and selecting optimal therapeutics.
  • CONCLUSION: The understanding of altered pathways in ameloblastoma may soon provide nonsurgical options for the treatment of this condition.
  • Thus, tumors that entirely depend on active SHH signaling for survival/growth and maintenance may well be susceptible targets for combined chemotherapy with SHH-specific inhibitors together with PI3K, Akt, or mTOR blocking agents.
  • [MeSH-major] Ameloblastoma / drug therapy. Signal Transduction / drug effects
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Hedgehog Proteins / antagonists & inhibitors. Hedgehog Proteins / physiology. Humans. Intracellular Signaling Peptides and Proteins / antagonists & inhibitors. Intracellular Signaling Peptides and Proteins / physiology. Phosphatidylinositol 3-Kinases / antagonists & inhibitors. Phosphatidylinositol 3-Kinases / physiology. Protein-Serine-Threonine Kinases / antagonists & inhibitors. Protein-Serine-Threonine Kinases / physiology. Proto-Oncogene Proteins c-akt / antagonists & inhibitors. Proto-Oncogene Proteins c-akt / physiology. TOR Serine-Threonine Kinases. Transcription Factors / antagonists & inhibitors. Transcription Factors / physiology

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2010 Mosby, Inc. All rights reserved.
  • (PMID = 20418126.001).
  • [ISSN] 1528-395X
  • [Journal-full-title] Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics
  • [ISO-abbreviation] Oral Surg Oral Med Oral Pathol Oral Radiol Endod
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / GLI1 protein, human; 0 / Hedgehog Proteins; 0 / Intracellular Signaling Peptides and Proteins; 0 / SHH protein, human; 0 / Transcription Factors; EC 2.7.1.- / Phosphatidylinositol 3-Kinases; EC 2.7.1.1 / MTOR protein, human; EC 2.7.1.1 / TOR Serine-Threonine Kinases; EC 2.7.11.1 / Protein-Serine-Threonine Kinases; EC 2.7.11.1 / Proto-Oncogene Proteins c-akt
  •  go-up   go-down


8. Vigneswaran N, Fernandes R, Rodu B, Baughman RA, Siegal GP: Aggressive osteoblastoma of the mandible closely simulating calcifying epithelial odontogenic tumor. Report of two cases with unusual histopathologic findings. Pathol Res Pract; 2001;197(8):569-76
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Aggressive osteoblastoma of the mandible closely simulating calcifying epithelial odontogenic tumor. Report of two cases with unusual histopathologic findings.
  • Aggressive osteoblastoma is a rare bone-forming neoplasm composed of prominent epithelioid cells that demonstrate locally invasive growth with a high rate of recurrence but no metastatic potential.
  • Clinical, radiographic and pathologic features of mandibular aggressive osteoblastoma in a 21-year-old African-American male and a 12-year-old Caucasian female are presented.
  • Both tumors were resected with wide surgical margins and neither patient had adjuvant radiation or chemotherapy.
  • These tumors were composed of solid sheets of pleomorphic epithelioid cells, eosinophilic amorphous osteoid with foci of calcification, which closely simulated amyloid.
  • Differentiation of this tumor from histologically similar calcifying epithelial odontogenic tumor and low-grade osteosarcoma proved difficult.
  • [MeSH-major] Ameloblastoma / pathology. Mandibular Neoplasms / pathology. Osteoblastoma / pathology
  • [MeSH-minor] Adult. Biomarkers, Tumor / analysis. Child. Diagnosis, Differential. Epithelioid Cells / pathology. Female. Humans. Immunohistochemistry. Male. Osteoblasts / pathology. Osteocalcin / analysis. Vimentin / analysis

  • Genetic Alliance. consumer health - Calcifying Epithelial Odontogenic Tumor.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11518051.001).
  • [ISSN] 0344-0338
  • [Journal-full-title] Pathology, research and practice
  • [ISO-abbreviation] Pathol. Res. Pract.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Vimentin; 104982-03-8 / Osteocalcin
  •  go-up   go-down


9. Huguet P, Castellví J, Avila M, Alejo M, Autonell F, Basas C, Bescos MS: Ameloblastic fibrosarcoma: report of a case. Immunohistochemical study and review of the literature. Med Oral; 2001 May-Jul;6(3):173-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ameloblastic fibrosarcoma: report of a case. Immunohistochemical study and review of the literature.
  • Ameloblastic fibrosarcoma is a rare malignant odontogenic tumour characterized by a benign epithelial component within a malignant fibrous stroma.
  • Its behaviour is relatively benign, with absence of metastatic disease, and the prognosis is reported to be good.
  • It is a paradoxical neoplasm with "sarcomatous" morphological and immunohistochemical patterns but with a favourable clinical course.
  • We report a new case of this tumour in a mandibular ramus of a 31-years-old male patient, that was surgically excised and treated with adjuvant chemotherapy and radiotherapy.
  • Five years later the patient is free of disease.
  • The growth potential of ameloblastic fibrosarcoma is evaluated and compared with a related lesion, the ameloblastic fibroma.
  • [MeSH-major] Mandibular Neoplasms / pathology. Odontogenic Tumors / pathology
  • [MeSH-minor] Adult. Chemotherapy, Adjuvant. Epithelial Cells / pathology. Follow-Up Studies. Humans. Immunohistochemistry. Ki-67 Antigen / analysis. Male. Mesoderm / pathology. Prognosis. Proliferating Cell Nuclear Antigen / analysis. Radiotherapy, Adjuvant. Tumor Suppressor Protein p53 / analysis

  • Genetic Alliance. consumer health - Fibrosarcoma.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11500634.001).
  • [ISSN] 1137-2834
  • [Journal-full-title] Medicina oral : órgano oficial de la Sociedad Española de Medicina Oral y de la Academia Iberoamericana de Patología y Medicina Bucal
  • [ISO-abbreviation] Med Oral
  • [Language] eng; spa
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Ki-67 Antigen; 0 / Proliferating Cell Nuclear Antigen; 0 / Tumor Suppressor Protein p53
  • [Number-of-references] 16
  •  go-up   go-down






Advertisement